Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California (NASDAQ:PACB) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Does the MarketBeat Community favor PACB or HBIO?

Pacific Biosciences of California received 83 more outperform votes than Harvard Bioscience when rated by MarketBeat users. However, 72.02% of users gave Harvard Bioscience an outperform vote while only 66.32% of users gave Pacific Biosciences of California an outperform vote.

Company	Underperform	Outperform
Pacific Biosciences of California	Outperform Votes 451 66.32%	Underperform Votes 229 33.68%
Harvard Bioscience	Outperform Votes 368 72.02%	Underperform Votes 143 27.98%

Do analysts rate PACB or HBIO?

Pacific Biosciences of California currently has a consensus target price of $2.79, indicating a potential upside of 109.90%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, equities analysts clearly believe Pacific Biosciences of California is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	0 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.54
Harvard Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has higher earnings and valuation, PACB or HBIO?

Harvard Bioscience has lower revenue, but higher earnings than Pacific Biosciences of California. Harvard Bioscience is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$154.01M	2.36	-$308.65M	-$1.64	-0.81
Harvard Bioscience	$97.73M	0.37	-$3.41M	-$0.33	-2.48

Is PACB or HBIO more profitable?

Harvard Bioscience has a net margin of -14.57% compared to Pacific Biosciences of California's net margin of -200.40%. Harvard Bioscience's return on equity of -4.64% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-200.40%	-42.89%	-14.77%
Harvard Bioscience	-14.57%	-4.64%	-2.40%

Which has more risk & volatility, PACB or HBIO?

Pacific Biosciences of California has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in PACB or HBIO?

80.9% of Harvard Bioscience shares are held by institutional investors. 2.4% of Pacific Biosciences of California shares are held by insiders. Comparatively, 9.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media favor PACB or HBIO?

In the previous week, Pacific Biosciences of California and Pacific Biosciences of California both had 2 articles in the media. Pacific Biosciences of California's average media sentiment score of 0.91 beat Harvard Bioscience's score of -0.50 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Pacific Biosciences of California beats Harvard Bioscience on 9 of the 17 factors compared between the two stocks.